scholarly journals Parents' views on their children's use of eye drops and willingness to accept a new sustained-release subconjunctival injection

2017 ◽  
Vol Volume 11 ◽  
pp. 1903-1909 ◽  
Author(s):  
Semra Ozdemir ◽  
Hong King Wu ◽  
Eric A. Finkelstein ◽  
Tina Wong
Keyword(s):  
Sustained Release ◽  
Willingness To Accept ◽  
Eye Drops ◽  
Subconjunctival Injection

A Comparative Study Between Preoperative Subconjunctival Bevacizumab Injection And Postoperative Topical Application In Prevention Of Recurrence After Excision Of Primary Pterygium In Egyptian Patients

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Basma Helal Mohamed ◽  
Othman Ali Othman Ziko ◽  
Hisham M Khairy Abd El Dayem ◽  
Nancy Ezzelregal Khamis Ahmed
Keyword(s):  
Corneal Thickness ◽  
Anterior Segment ◽  
P Value ◽  
Eye Drops ◽  
Subconjunctival Injection ◽  
Fibrovascular Tissue ◽  
Significant Difference ◽  
Group 2 ◽  
Group 1 ◽  
Primary Pterygium

Abstract Purpose to compare between recurrence incidence after primary pterygium excision when using preoperative subconjunctival injection of Bevacizumab (Avastin) and using it as a postoperative eye drops. Methods thirty two eyes of thirty patients (two patients had bilateral pterygium) with primary pterygia were clinically examined, classified into 3 groups and operated by simple excision with bare sclera technique. Group 1 included 10 patients received Bevacizumab (Avastin) in the form of eye drops (10 mg/ml) 3 times daily for 6 days postoperative. Group 2 included 10 patients received preoperative Bevacizumab in the form of subconjunctival injection (1.25 mg/0.05ml) single dose 1 week preoperative. Group 3 included 10 patients (12 eyes) 2 patients with bilateral Pterygium didn’t receive any form of Bevacizumab. Postoperative follow up was done clinically and by serial photography at 1 week, 1 month, 3 months and 6 months searching for signs of recurrence and/or complications. Results The results showed different grades of recurrence in 18 eyes of 32.True recurrence was seen in 7 patients of 18 (1 patient in group 1, 2 in group 2 and 4 in group3).Recurrence grades in group 1and 2 who used the Bevacizumab (20%grade II, 50% grade III, and 30% grade IV). Recurrence could be predicted by 100% depending on fibrovascular tissue appearing in the surgical bed at 3 months postoperative (P value 0.038).Preoperative fleshy pterygium has high statistical significance in realation to recurrence(P value = 0.006).Patient’s sex, residence and occupation had no statistically significant value in the process of recurrence (P value > 0.05). Patients with recurrent Pterygia (in group 1&2) had statistically significant changes in the corneal K- readings at 3 months and 6 months.No significant difference in the limbal or central corneal thickness in the operated eye and the other eye (Pvalue > 0.05). Conclusion Bevacizumab (Avastin) is a well tolerated drug with multiple drug delivery methods.The eye drops give better results than the subconjunctival injection.Appearance of fibrovascular tissue in the surgical bed at 3 months predict the recurrence by 100%. Preoperative fleshy pterygia will mostly recur again whatever Bevacizumab form was used .The corneal thickness by anterior segment OCT has no role in prediction or detection of early pterygium recurrence.

scholarly journals Sustained-release voriconazole-thermogel for subconjunctival injection in horses: ocular toxicity and in-vivo studies

2020 ◽  
Vol 16 (1) ◽  
Author(s):  
Mariano Mora-Pereira ◽  
Eva M. Abarca ◽  
Sue Duran ◽  
William Ravis ◽  
Richard J. McMullen ◽  
...  
Keyword(s):  
Sustained Release ◽  
In Vivo Studies ◽  
Subconjunctival Injection ◽  
Ocular Toxicity

scholarly journals Pluripotent epigenetic regulator OBP-801 maintains filtering blebs in glaucoma filtration surgery model

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Yuji Yamamoto ◽  
Atsushi Mukai ◽  
Toru Ikushima ◽  
Yasuo Urata ◽  
Shigeru Kinoshita ◽  
...  
Keyword(s):  
Wound Healing ◽  
Rabbit Model ◽  
Vehicle Control ◽  
Control Group ◽  
Eye Drops ◽  
Subconjunctival Injection ◽  
Filtration Surgery ◽  
Glaucoma Filtration Surgery ◽  
Vehicle Control Group ◽  
Epigenetic Regulator

AbstractInhibition of fibrosis is indispensable for maintaining filtering blebs after glaucoma filtration surgery (GFS). The purpose of this study was to investigate the ability of a pluripotent epigenetic regulator OBP-801 (OBP) to ameliorate extracellular matrix formation in a rabbit model of GFS. Rabbits that underwent GFS were treated with OBP. The gene expression profiles and intraocular pressure (IOP) were monitored until 30 postoperative days. The bleb tissues were evaluated for tissue fibrosis at 30 postoperative days. In in vitro models, OBP interfered the functions of diverse genes during the wound-healing process. In in vivo GFS models, the expressions of TGF-β3, MMP-2, TIMP-2 and 3, LOX, COL1A and SERPINH1 were significantly inhibited at 30 postoperative days in the OBP group compared with those in the vehicle control group. OBP treatment involving subconjunctival injection or eye drops showed no adverse effects, and reduced levels of α-SMA and collagen deposition at the surgical wound site. OBP maintained the long-lived bleb without scar formation, and IOP was lower at 30 postoperative days compared with the vehicle control group. These findings suggest that OBP is an effective and useful candidate low-molecular-weight agent for improving wound healing and surgical outcomes in a rabbit model of GFS.

scholarly journals Development of a Sustained-Release Voriconazole-Containing Thermogel for Subconjunctival Injection in Horses

2017 ◽  
Vol 58 (5) ◽  
pp. 2746 ◽  
Author(s):  
Rosemary S. Cuming ◽  
Eva M. Abarca ◽  
Sue Duran ◽  
Anne A. Wooldridge ◽  
Allison J. Stewart ◽  
...  
Keyword(s):  
Sustained Release ◽  
Subconjunctival Injection

scholarly journals Umbilical mesenchymal stem cells attenuates corneal fibrosis induced by fungal keratitis through the TGFβ1/Smad2 signaling pathway

2019 ◽  
Author(s):  
Yue Zhou ◽  
Yuqing Chen ◽  
Suiyue Wang ◽  
Fangyuan Qin ◽  
Wang liya
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Signaling Pathway ◽  
Umbilical Cord ◽  
Fungal Keratitis ◽  
Scar Formation ◽  
Human Umbilical Cord ◽  
Eye Drops ◽  
Subconjunctival Injection ◽  
Corneal Scar

Abstract Background: Fungal keratitis (FK) is eye microbial infection disease which can leads to severe corneal blindness. Corneal scar formation is one of the major complications of fungal keratitis and is closely related to prognosis. The aim of the current investigation was to evaluate the anti-fibrosis effect of human umbilical cord mesenchymal stem cells (uMSCs) in FK model and further to explore underlying mechanisms. Methods: FK mice model was made by corneal epithelial scratching and F. solani inoculation. The C57BL/6J mice were randomly divided into four groups, including control group, FK group, vehicleinj FK group and uMSCsinj FK group. After injury, antifungal drug natamycin eye drops were used topically to FK mice eyes 6 times per day for 7 days to inhibit fungi growth. Mice received repeated subconjunctival injection of uMSCs or veichle for 3 times including the 1d, 4d and 7d after wounding. At 14d, 21d and 28d post-injury, clinical observation, histological examination, second harmonic generation, immunofluoresence staining and molecular assays were performed. Results: The uMSCs topical administration reduced corneal scar formation and corneal opacity, accompanying with decreased corneal thickness and inflammatory cell infiltration, following down-regulated fibrotic-related factors α-SMA, TGFβ1, CTGF, and COLⅠ and finally inhibited phosphorylation of TGFβ1/Smad2 signaling pathway, which indicating the potential anti-fibrotic and protective effect of human uMSCs against FK-induced corneal fibrosis. Conclusion: Human uMSCs can evidently inhibit corneal fibrosis after FK wounding through TGFβ1/Smad2 signaling pathway regulation. Keywords: Fungal keratitis, corneal fibrosis, umbilical cord mesenchymal stem cells

scholarly journals Development of Sustained-Release Ophthalmic Formulation Based on Tranilast Solid Nanoparticles

Materials ◽  
2020 ◽  
Vol 13 (7) ◽  
pp. 1675 ◽  
Author(s):  
Misa Minami ◽  
Ryotaro Seiriki ◽  
Hiroko Otake ◽  
Yosuke Nakazawa ◽  
Kazutaka Kanai ◽  
...  
Keyword(s):  
Sustained Release ◽  
Release Profile ◽  
Eye Drops ◽  
Upper Eyelid ◽  
Thermal Stabilities ◽  
Release Drug ◽  
Eyelid Skin ◽  
Bead Mill ◽  
Gel Formulations ◽  
Ophthalmic Formulation

Eye drops containing Tranilast (TL), N-(3,4-dimethoxycinnamoyl) anthramilic acid, are used as an anti-allergic conjunctivitis drug in the ophthalmic field. Traditional eye drops are very patient compliant, although the bioavailability (BA) of most eye drops is low since eye drops cannot be instilled beyond the capacity of the conjunctival sac due to its limited volume. Thus, traditional eye drops have low BA and a short duration of the drug on the ocular surface, so solutions to these problems are highly anticipated. In this study, we designed a sustained-release drug-delivery system (DDS) for TL nanoparticles. TL nanoparticles were prepared by bead mill treatment, and the gel formulations containing TL nanoparticles (TL-NPs-Gel, particle size 50 nm–100 nm) were provided by carboxypolymethylene. The crystal structure of TL with and without bead mill treatment is the same, but the TL solubility in formulations containing nanoparticles was 5.3-fold higher compared with gel formulations containing TL microparticles (TL-MPs-Gel). The photo and thermal stabilities of TL-NPs-Gel are also higher than those of dissolved TL. Moreover, when TL-NPs-Gel is applied to the upper eyelid skin (outside), the TL is released as nanoparticles, and delivered to the lacrimal fluid through the meibomian glands. In addition, the TL release profile for TL-NPs-Gel was sustained over 180 min after the treatment. These findings can be used to develop a sustained-release DDS in the ophthalmic field.

1558: Local Injection of Sustained-Release Antiandrogen Formulation into a Target Prostatic Site: An Experimental Study

2007 ◽  
Vol 177 (4S) ◽  
pp. 515-515
Author(s):  
Nobuyuki Goya ◽  
Kotara Gotanda ◽  
Yasuko Tomizawa ◽  
Hiroshi Toma
Keyword(s):  
Experimental Study ◽  
Sustained Release ◽  
Local Injection
Sign in / Sign up

Export Citation Format

Share Document